CTIS2022-502807-31-00招募中1 期
Exploratory pilot study to determine the tolerability and effectiveness of Tirbanibulin in the treatment of Actinic Cheilitis - TUD-AKTCHE-082
Technische Universitat Dresden0 个研究点目标入组 20 人开始时间: 2023年5月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years, Newly diagnosed Actinic Cheilitis (clinically and by optical coherence tomography) or chronic Actinic Cheilitis at the time of registration (Clinic: atrophy of the lip (white coloration) or adhering , hyperkeratotic plaques or erosions; OCT: thickening of epidermis and increase in signal penetration and intact dermoepidermal junction zone), Skin type I to III (Fitzpatrick scale), Written informed consent after clarification
排除标准
- •Known genetic defect of the epidermal barrier (e.g. Netherton-Syndrome), Local enteritis, ulcerative colitis or known antibiotic-associated colitis, Current or previous invasive squamous cell carcinoma of the respective lip intended for treatment, Active cancer disease, Known hypersensitivity towards the medicinal product under investigation or one of its components or towards medications of a similar chemical structure, Participation in another interventional clinical trial (up to 4 weeks before start of therapy), Addiction or other concomitant diseases, which prevent the participant from understanding and comprehending the scope, nature and potential consequences of this clinical trial, Pregnant or lactating women, Male participants with partners of childbearing potential, not meeting at least one of the following criteria: Postmenopausal (12 months of amenorrhea by natural causes, or 6 months of amenorrhea in combination with a highly effective contraception method (Pearl Index <1%)); Post-surgery (6 weeks after bilateral ovariectomy, bilateral salpingectomy with or without a hysterectomy); Negative pregnancy test (urine, minimum sensitivity for Beta-HCG 25mIU/ml) and willingness to regularly and correctly use a highly effective contraceptive method (Pearl Index < 1 %) ((hormonal contraception (estrogen- gestagen combinations), hormonal contraception (progestogen preparations, oral, injected, implant), spiral (hormonal coil, copper IUD), confirmed partner’s vasectomy, abstinence from study incusion unitl final visit )), Women of childbearing potential, except for women who meet at least one of the following criteria: Postmenopausal (12 months of amenorrhea by natural causes, or 6 months of amenorrhea in combination with a highly effective contraception method (Pearl Index <1%)); Post-surgery (6 weeks after bilateral ovariectomy, bilateral salpingectomy with or without a hysterectomy); Negative pregnancy test (urine, minimum required sensitivity for Beta-HCG 25mIU/ml Beta-HCG) and willingness to regularly and correctly use a highly effective contraceptive method (Pearl Index < 1 %) ((hormonal contraception (estrogen- gestagen combinations), hormonal contraception (progestogen preparations, oral, injected, implant), spiral (hormonal coil, copper IUD), confirmed sucessfull partner’s vasectomy, abstinence from study inclusion until the final visit)), Individuals who are unable to give consent, Signs of facial skin irritation (significant redness, dryness, burning sensation, stabbing sensation, pruritus) which cannot be attributed to Actinic Cheilitis, Individuals, who are dependent from the sponsor, Individuals, who are institutionalized or imprisoned by court order or other official institution, Any indication that the subject is unlikely to adhere to the protocol (e.g. lack of compliance), Simultaneous treatment with topical preparations (including cosmetics) or keratolytic substances (e.g. sulphur, salicylic acid, benzoyl peroxide, resorcine and chemical abrasives), soaps with peeling and strongly dehydrating effects, perfumes, citrus extracts, topical antibiotics, corticosteroids, retinoid or azalaic acid within 2 weeks before start of trial intervention (day 0), Intensive natural or artificial UV light therapy (e.g. UVB, UVA, PUVA) within 4 weeks before start of trial intervention (day 0), Intake of antibiotics or glucocorticosteroids within 4 weeks before start of trial intervention (day 0), Intake of retinoids within 6 months
研究者
相似试验
进行中（未招募）
不适用
Esplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - NDEUCTR2010-019194-15-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
已完成
不适用
A pilot study to assess the tolerability and the effectiveness of combination treatment of olanzapine and escitalpram for bipolar depression in Japamajor depressive episode of bipolar disorderJPRN-UMIN000014204Department of Psychiatry, Hokkaido University Hospital60
撤回
不适用
A phase I study to determine the maximum tolerable dose (MTD) of weekly carboplatin with the Wee1 inhibitor AZD1775 in patients with p53 mutated solid tumors.NL-OMON45937Antoni van Leeuwenhoek Ziekenhuis30
已完成
1 期
A study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphomaCancerISRCTN42054893niversity of Birmingham (UK)58
进行中（未招募）
1 期
A phase I/II study to find the safe dose of the combination of romidepsin and carfilzomib (phase I) in patients with relapsed or refractory T-Cell lymphoma. The phase II part of the study will look at the activity of the combination.Peripheral T-cell LymphomaMedDRA version: 20.0Level: PTClassification code 10034626Term: Peripheral T-cell lymphoma unspecified refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10034625Term: Peripheral T-cell lymphoma unspecified recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001879-20-GBniversity of Birmingham57